Movement Alert｜CSPC Pharmaceutical Rises 3.31% in Regular Trading, AstraZeneca Strategic Partnership and Multiple Pipeline Milestones Fuel Sentiment

Market Focus

8 hours ago

On July 3, CSPC Pharmaceutical rose 3.31% in regular trading, trading at HKD 7.95/share, with turnover of HKD 108 million. The stock continued to rally as markets digested a wave of positive developments announced the prior day.

On July 2, CSPC entered a strategic collaboration, option and license agreement with AstraZeneca covering its siRNA drug discovery and extrahepatic targeted delivery platforms for renal disease treatment. Under the deal, CSPC will receive USD 30 million upfront, up to USD 540 million in development milestones, up to USD 1.2 billion in sales milestones, and single-digit royalties. Additionally, CSPC's ADC drug SYS6043 was granted breakthrough therapy designation for platinum-resistant ovarian cancer, its iron sucrose injection obtained marketing approval, and its recombinant herpes zoster vaccine received clinical trial approval in China.

Within the Pharmaceuticals sector, the broader group strengthened in tandem. Among peers, Hansoh Pharma rose 4.79%, Hengrui Pharma rose 4.04%, and Luye Pharma rose 3.76%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1161870090"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1161870090\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1161870090?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-03 09:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161870090","market":"us","top_or_hot":-1,"title":"Movement Alert｜CSPC Pharmaceutical Rises 3.31% in Regular Trading, AstraZeneca Strategic Partnership and Multiple Pipeline Milestones Fuel Sentiment","media":"Market Focus","content":"<p><p>On July 3, CSPC Pharmaceutical rose 3.31% in regular trading, trading at HKD 7.95/share, with turnover of HKD 108 million. The stock continued to rally as markets digested a wave of positive developments announced the prior day.</p><p>On July 2, CSPC entered a strategic collaboration, option and license agreement with AstraZeneca covering its siRNA drug discovery and extrahepatic targeted delivery platforms for renal disease treatment. Under the deal, CSPC will receive USD 30 million upfront, up to USD 540 million in development milestones, up to USD 1.2 billion in sales milestones, and single-digit royalties. Additionally, CSPC's ADC drug SYS6043 was granted breakthrough therapy designation for platinum-resistant ovarian cancer, its iron sucrose injection obtained marketing approval, and its recombinant herpes zoster vaccine received clinical trial approval in China.</p><p>Within the Pharmaceuticals sector, the broader group strengthened in tandem. Among peers, Hansoh Pharma rose 4.79%, Hengrui Pharma rose 4.04%, and Luye Pharma rose 3.76%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜CSPC Pharmaceutical Rises 3.31% in Regular Trading, AstraZeneca Strategic Partnership and Multiple Pipeline Milestones Fuel Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜CSPC Pharmaceutical Rises 3.31% in Regular Trading, AstraZeneca Strategic Partnership and Multiple Pipeline Milestones Fuel Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-03 09:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 3, CSPC Pharmaceutical rose 3.31% in regular trading, trading at HKD 7.95/share, with turnover of HKD 108 million. The stock continued to rally as markets digested a wave of positive developments announced the prior day.</p><p>On July 2, CSPC entered a strategic collaboration, option and license agreement with AstraZeneca covering its siRNA drug discovery and extrahepatic targeted delivery platforms for renal disease treatment. Under the deal, CSPC will receive USD 30 million upfront, up to USD 540 million in development milestones, up to USD 1.2 billion in sales milestones, and single-digit royalties. Additionally, CSPC's ADC drug SYS6043 was granted breakthrough therapy designation for platinum-resistant ovarian cancer, its iron sucrose injection obtained marketing approval, and its recombinant herpes zoster vaccine received clinical trial approval in China.</p><p>Within the Pharmaceuticals sector, the broader group strengthened in tandem. Among peers, Hansoh Pharma rose 4.79%, Hengrui Pharma rose 4.04%, and Luye Pharma rose 3.76%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01093","symbol_name":"石药集团","start_time":0,"source_url":"","article_id":"1161870090","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161870090","pubTimestamp":1783042432,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 3, CSPC Pharmaceutical rose 3.31% in regular trading, trading at HKD 7.95/share, with turnover of HKD 108 million. The stock continued to rally as markets digested a wave of positive...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01093":"石药集团"},"translate_title":"动向提示|石药集团常规交易涨3.31%阿斯利康战略合作伙伴关系及多个管线里程碑提振人气","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1},"content_text":"On July 3, CSPC Pharmaceutical rose 3.31% in regular trading, trading at HKD 7.95/share, with turnover of HKD 108 million. The stock continued to rally as markets digested a wave of positive developments announced the prior day.On July 2, CSPC entered a strategic collaboration, option and license agreement with AstraZeneca covering its siRNA drug discovery and extrahepatic targeted delivery platforms for renal disease treatment. Under the deal, CSPC will receive USD 30 million upfront, up to USD 540 million in development milestones, up to USD 1.2 billion in sales milestones, and single-digit royalties. Additionally, CSPC's ADC drug SYS6043 was granted breakthrough therapy designation for platinum-resistant ovarian cancer, its iron sucrose injection obtained marketing approval, and its recombinant herpes zoster vaccine received clinical trial approval in China.Within the Pharmaceuticals sector, the broader group strengthened in tandem. Among peers, Hansoh Pharma rose 4.79%, Hengrui Pharma rose 4.04%, and Luye Pharma rose 3.76%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}